SCPS Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Scopus BioPharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.064 |
| 52 Week Low | US$0.000001 |
| Beta | 38.66 |
| 11 Month Change | -40.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.41% |
| 33 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| SCPS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -99.4% | 15.6% | 30.7% |
Return vs Industry: SCPS underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: SCPS underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| SCPS volatility | |
|---|---|
| SCPS Average Weekly Movement | 181.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCPS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SCPS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 13 | n/a | scopusbiopharma.com |
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein.
Scopus BioPharma Inc. Fundamentals Summary
| SCPS fundamental statistics | |
|---|---|
| Market cap | US$12.63k |
| Earnings (TTM) | -US$8.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs SCPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCPS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.70m |
| Earnings | -US$8.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SCPS perform over the long term?
See historical performance and comparison